Relmada Therapeutics/RLMD

$5.68

2.52%
-
1D1W1MYTD1YMAX

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive and monotherapy treatment of major depressive disorder.
Ticker
RLMD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Sergio Traversa
Employees
14
Headquarters
Coral gables, United States

RLMD Metrics

BasicAdvanced
$170.96M
Market cap
-
P/E ratio
-$3.71
EPS
0.20
Beta
-
Dividend rate

What the Analysts think about RLMD

Analyst Ratings

Majority rating from 5 analysts.
Hold

Price Targets

Average projection from 4 analysts.
82.75% upside
High $25.00
Low $3.00
$5.68
Current price
$10.38
Average price target

RLMD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-22M
-13.04%
Profit margin
0%
-

RLMD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.04%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.41
-$0.87
-$0.84
-$0.73
-
Expected
-$1.33
-$0.89
-$0.90
-$0.91
-$0.83
Surprise
6.2%
-2.16%
-6.34%
-20.04%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Relmada Therapeutics stock

Buy or sell Relmada Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing